{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T02:25:14Z","timestamp":1787883914815,"version":"build-2784847793"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-03143-z","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T06:24:31Z","timestamp":1763619871000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["BH3 mimetic and dual PI3K\/mTOR inhibitor attenuates gemcitabine resistance in triple-negative breast cancer"],"prefix":"10.1007","volume":"43","author":[{"given":"Gizem","family":"Selimoglu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suranur","family":"Ayvaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeynep Busra","family":"Bolat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,20]]},"reference":[{"key":"3143_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"3143_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106535","volume":"84","author":"K Barzaman","year":"2020","unstructured":"Barzaman K, Karami J, Zarei Z, Hosseinzadeh A, Kazemi MH, Moradi-Kalbolandi S, et al. Breast cancer: biology, biomarkers, and treatments. Int Immunopharmacol. 2020;84:106535.","journal-title":"Int Immunopharmacol"},{"key":"3143_CR3","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","volume":"22","author":"L Yin","year":"2020","unstructured":"Yin L, Duan J-J, Bian X-W, Yu S. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020;22:61.","journal-title":"Breast Cancer Res"},{"key":"3143_CR4","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2147\/CMAR.S146658","volume":"10","author":"C Omarini","year":"2018","unstructured":"Omarini C, Guaitoli G, Pipitone S, Moscetti L, Cortesi L, Cascinu S, et al. Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going. Cancer Manag Res. 2018;10:91\u2013103.","journal-title":"Cancer Manag Res"},{"key":"3143_CR5","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.3892\/ijo.2020.5135","volume":"57","author":"K-A Won","year":"2020","unstructured":"Won K-A, Spruck C. Triple\u2013negative breast cancer therapy: current and future perspectives (Review). Int J Oncol. 2020;57:1245\u201361.","journal-title":"Int J Oncol"},{"key":"3143_CR6","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.3390\/pharmaceutics12121193","volume":"12","author":"P Lainetti","year":"2020","unstructured":"Lainetti P, de F, Leis-Filho AF, Laufer-Amorim R, Battazza A, Fonseca-Alves CE. Mechanisms of resistance to chemotherapy in breast cancer and possible targets in drug delivery systems. Pharmaceutics. 2020;12:1193.","journal-title":"Pharmaceutics"},{"key":"3143_CR7","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejphar.2014.07.041","volume":"741","author":"L de Sousa Cavalcante","year":"2014","unstructured":"de Sousa Cavalcante L, Monteiro G. Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer. Eur J Pharmacol. 2014;741:8\u201316.","journal-title":"Eur J Pharmacol"},{"key":"3143_CR8","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1159\/000069315","volume":"64","author":"V Heinemann","year":"2003","unstructured":"Heinemann V. Role of gemcitabine in the treatment of advanced and metastatic breast cancer. Oncology. 2003;64:191\u2013206.","journal-title":"Oncology"},{"key":"3143_CR9","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1186\/s12935-022-02681-0","volume":"22","author":"Y Xi","year":"2022","unstructured":"Xi Y, Li T, Xi Y, Zeng X, Miao Y, Guo R, et al. Combination treatment with hENT1 and miR-143 reverses gemcitabine resistance in triple-negative breast cancer. Cancer Cell Int. 2022;22:271.","journal-title":"Cancer Cell Int"},{"key":"3143_CR10","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2020.12109","volume":"20","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, Jiang H, Gu M, Zu C, Zheng X. Gemcitabine resistance in triple-negative breast cancer cells can be reverted by Drosophila melanogaster deoxyribonucleoside kinase in the nucleus or cytosol. Oncol Lett. 2020;20:247.","journal-title":"Oncol Lett"},{"key":"3143_CR11","doi-asserted-by":"publisher","first-page":"957","DOI":"10.3390\/cells8090957","volume":"8","author":"M Nedeljkovi\u0107","year":"2019","unstructured":"Nedeljkovi\u0107 M, Damjanovi\u0107 A. Mechanisms of chemotherapy resistance in Triple-Negative breast cancer\u2014how we can rise to the challenge. Cells. 2019;8:957.","journal-title":"Cells"},{"key":"3143_CR12","first-page":"1083","volume":"40","author":"N Alqurashi","year":"2018","unstructured":"Alqurashi N, Hashimi SM, Alowaidi F, Ivanovski S, Wei MQ. Dual mTOR\/PI3K inhibitor NVP\u2013BEZ235 arrests colorectal cancer cell growth and displays differential inhibition of 4E\u2013BP1. Oncol Rep. 2018;40:1083\u201392.","journal-title":"Oncol Rep"},{"key":"3143_CR13","doi-asserted-by":"publisher","unstructured":"Yasumizu Y, Miyajima A, Kosaka T, Miyazaki Y, Kikuchi E, Oya M. Dual PI3K\/mTOR Inhibitor NVP-BEZ235 Sensitizes Docetaxel in Castration Resistant Prostate Cancer. The Journal of Urology [Internet]. 2014 [cited 2025 Jan 22]; Available from: https:\/\/www.auajournals.org\/doi\/https:\/\/doi.org\/10.1016\/j.juro.2013.07.101","DOI":"10.1016\/j.juro.2013.07.101"},{"key":"3143_CR14","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2021.11940","volume":"23","author":"J Li","year":"2021","unstructured":"Li J, Wang X, Ma C, Xu S, Xu M, Yang J, et al. Dual PI3K\/mTOR inhibitor NVP\u2011BEZ235 decreases the proliferation of doxorubicin\u2011resistant K562 cells. Mol Med Rep. 2021;23:301.","journal-title":"Mol Med Rep"},{"key":"3143_CR15","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2020.12189","volume":"20","author":"H Zhu","year":"2020","unstructured":"Zhu H, Shi Y, Jiao X, Yang G, Wang R, Yuan Y. Synergistic antitumor effect of dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with cisplatin on drug-resistant non-small cell lung cancer cell. Oncol Lett. 2020;20:326.","journal-title":"Oncol Lett"},{"key":"3143_CR16","first-page":"3457","volume":"34","author":"HS Park","year":"2014","unstructured":"Park HS, Hong SK, Oh MM, Yoon CY, Jeong SJ, Byun SS, et al. Synergistic antitumor effect of NVP-BEZ235 and Sunitinib on docetaxel-resistant human castration-resistant prostate cancer cells. Anticancer Res. 2014;34:3457\u201368.","journal-title":"Anticancer Res"},{"key":"3143_CR17","doi-asserted-by":"publisher","first-page":"240","DOI":"10.4174\/astr.2018.95.5.240","volume":"95","author":"E Hwang","year":"2018","unstructured":"Hwang E, Hwang S-H, Kim J, Park JH, Oh S, Kim YA, et al. ABT-737 ameliorates docetaxel resistance in triple negative breast cancer cell line. Ann Surg Treat Res. 2018;95:240\u20138.","journal-title":"Ann Surg Treat Res"},{"key":"3143_CR18","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1038\/sj.onc.1210028","volume":"26","author":"D Chauhan","year":"2007","unstructured":"Chauhan D, Velankar M, Brahmandam M, Hideshima T, Podar K, Richardson P, et al. A novel Bcl-2\/Bcl-XL\/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene. 2007;26:2374\u201380.","journal-title":"Oncogene"},{"key":"3143_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2019.116561","volume":"232","author":"L Hou","year":"2019","unstructured":"Hou L, Wang R, Wei H, Li S, Liu L, Lu X, et al. ABT737 enhances ovarian cancer cells sensitivity to cisplatin through regulation of mitochondrial fission via Sirt3 activation. Life Sci. 2019;232:116561.","journal-title":"Life Sci"},{"key":"3143_CR20","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1158\/1535-7163.MCT-10-1091","volume":"10","author":"C Zhang","year":"2011","unstructured":"Zhang C, Cai T, Zhu H, Yang L, Jiang H, Dong X, et al. Synergistic antitumor activity of gemcitabine and ABT-737 in vitro and in vivo through disrupting the interaction of USP9X and Mcl-1. Mol Cancer Ther. 2011;10:1264\u201375.","journal-title":"Mol Cancer Ther"},{"key":"3143_CR21","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.ccr.2006.08.027","volume":"10","author":"MF van Delft","year":"2006","unstructured":"van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE, et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak\/Bax if Mcl-1 is neutralized. Cancer Cell. 2006;10:389\u201399.","journal-title":"Cancer Cell"},{"issue":"4","key":"3143_CR22","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/CAD.0000000000000736","volume":"30","author":"E Avsar Abdik","year":"2019","unstructured":"Avsar Abdik E, Kaleagasioglu F, Abdik H, Sahin F, Berger MR. ABT-737 and erufosine combination against castration-resistant prostate cancer: a promising but cell-type specific response associated with the modulation of anti-apoptotic signaling. Anticancer Drugs. 2019;30(4):383\u201393.","journal-title":"Anticancer Drugs"},{"key":"3143_CR23","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.1158\/0008-5472.CAN-17-3024","volume":"78","author":"M Rahmani","year":"2018","unstructured":"Rahmani M, Nkwocha J, Hawkins E, Pei X, Parker RE, Kmieciak M, et al. Cotargeting BCL-2 and PI3K induces BAX-dependent mitochondrial apoptosis in AML cells. Cancer Res. 2018;78:3075\u201386.","journal-title":"Cancer Res"},{"key":"3143_CR24","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.7150\/ijbs.82000","volume":"19","author":"S Chan","year":"2023","unstructured":"Chan S, Wang X, Wang Z, Du Y, Zuo X, Chen J, et al. CTSG suppresses colorectal cancer progression through negative regulation of Akt\/mTOR\/Bcl2 signaling pathway. Int J Biol Sci. 2023;19:2220\u201333.","journal-title":"Int J Biol Sci"},{"key":"3143_CR25","doi-asserted-by":"publisher","unstructured":"McDermott M, Eustace A, Busschots S, Breen L, Clynes M, O\u2019Donovan N et al. In vitro Development of Chemotherapy and Targeted Therapy Drug-Resistant Cancer Cell Lines: A Practical Guide with Case Studies. Frontiers in Oncology [Internet]. 2014 [cited 2023 Oct 25];4. Available from: https:\/\/www.frontiersin.org\/articles\/https:\/\/doi.org\/10.3389\/fonc.2014.00040","DOI":"10.3389\/fonc.2014.00040"},{"key":"3143_CR26","doi-asserted-by":"publisher","first-page":"398","DOI":"10.3892\/ijo.2015.3019","volume":"47","author":"W Wattanawongdon","year":"2015","unstructured":"Wattanawongdon W, Hahnvajanawong C, Namwat N, Kanchanawat S, Boonmars T, Jearanaikoon P, et al. Establishment and characterization of gemcitabine-resistant human cholangiocarcinoma cell lines with multidrug resistance and enhanced invasiveness. Int J Oncol. 2015;47:398\u2013410.","journal-title":"Int J Oncol"},{"key":"3143_CR27","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.58.3.10","volume":"58","author":"T-C Chou","year":"2006","unstructured":"Chou T-C, Theoretical, Basis. Experimental Design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58:621\u201381.","journal-title":"Pharmacol Rev"},{"key":"3143_CR28","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","volume":"22","author":"T-C Chou","year":"1984","unstructured":"Chou T-C, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27\u201355.","journal-title":"Adv Enzyme Regul"},{"key":"3143_CR29","doi-asserted-by":"publisher","first-page":"105958","DOI":"10.1016\/j.tiv.2024.105958","volume":"102","author":"Z Demirci","year":"2025","unstructured":"Demirci Z, Islek Z, Siginc HI, Sahin F, Ucisik MH, Bolat ZB. Curcumin-loaded emulsome nanoparticles induces apoptosis through p53 signaling pathway in pancreatic cancer cell line PANC-1. Toxicol Vitro. 2025;102:105958.","journal-title":"Toxicol Vitro"},{"key":"3143_CR30","doi-asserted-by":"publisher","first-page":"W242","DOI":"10.1093\/nar\/gkab418","volume":"49","author":"C Li","year":"2021","unstructured":"Li C, Tang Z, Zhang W, Ye Z, Liu F. GEPIA2021: integrating multiple deconvolution-based analysis into GEPIA. Nucleic Acids Res. 2021;49:W242\u20136.","journal-title":"Nucleic Acids Res"},{"key":"3143_CR31","doi-asserted-by":"publisher","first-page":"54","DOI":"10.4048\/jbc.2017.20.1.54","volume":"20","author":"K-T Hwang","year":"2017","unstructured":"Hwang K-T, Han W, Kim J, Moon H-G, Oh S, Song YS, et al. Prognostic influence of BCL2 on molecular subtypes of breast cancer. J Breast Cancer. 2017;20:54\u201364.","journal-title":"J Breast Cancer"},{"key":"3143_CR32","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nature03579","volume":"435","author":"T Oltersdorf","year":"2005","unstructured":"Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005;435:677\u201381.","journal-title":"Nature"},{"key":"3143_CR33","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1667\/RR13856.1","volume":"182","author":"H Wu","year":"2014","unstructured":"Wu H, Schiff DS, Lin Y, Neboori HJR, Goyal S, Feng Z, et al. Ionizing radiation sensitizes breast cancer cells to Bcl-2 inhibitor, ABT-737, through regulating Mcl-1. Radiat Res. 2014;182:618\u201325.","journal-title":"Radiat Res"},{"key":"3143_CR34","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.canlet.2014.03.001","volume":"348","author":"A Jebahi","year":"2014","unstructured":"Jebahi A, Villedieu M, P\u00e9tigny-Lechartier C, Brotin E, Louis M-H, Abeilard E, et al. PI3K\/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced. Cancer Lett. 2014;348:38\u201349.","journal-title":"Cancer Lett"},{"key":"3143_CR35","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.canlet.2012.11.013","volume":"339","author":"C Zang","year":"2013","unstructured":"Zang C, Eucker J, Liu H, M\u00fcller A, Possinger K, Scholz CW. Concurrent inhibition of PI3-kinase and mTOR induces cell death in diffuse large B cell lymphomas, a mechanism involving down regulation of Mcl-1. Cancer Lett. 2013;339:288\u201397.","journal-title":"Cancer Lett"},{"key":"3143_CR36","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1038\/sj.bjc.6601011","volume":"88","author":"AM Bergman","year":"2003","unstructured":"Bergman AM, Pinedo HM, Talianidis I, Veerman G, Loves WJP, van der Wilt CL, et al. Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines. Br J Cancer. 2003;88:1963\u201370.","journal-title":"Br J Cancer"},{"key":"3143_CR37","doi-asserted-by":"publisher","first-page":"e82363","DOI":"10.1371\/journal.pone.0082363","volume":"8","author":"Q Wang","year":"2013","unstructured":"Wang Q, Cui K, Espin-Garcia O, Cheng D, Qiu X, Chen Z, et al. Resistance to bleomycin in cancer cell lines is characterized by prolonged doubling time, reduced DNA damage and evasion of G2\/M arrest and apoptosis. PLoS One. 2013;8:e82363.","journal-title":"PLoS One"},{"key":"3143_CR38","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1093\/jnci\/91.21.1876","volume":"91","author":"JR Mackey","year":"1999","unstructured":"Mackey JR, Yao SY, Smith KM, Karpinski E, Baldwin SA, Cass CE, et al. Gemcitabine transport in xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters. J Natl Cancer Inst. 1999;91:1876\u201381.","journal-title":"J Natl Cancer Inst"},{"key":"3143_CR39","first-page":"203","volume":"8","author":"J Lane","year":"2010","unstructured":"Lane J, Martin TA, McGuigan C, Mason MD, Jiang WG. The differential expression of hCNT1 and hENT1 in breast cancer and the possible impact on breast cancer therapy. J Exp Ther Oncol. 2010;8:203\u201310.","journal-title":"J Exp Ther Oncol"},{"key":"3143_CR40","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1093\/carcin\/bgw093","volume":"37","author":"RA Hesler","year":"2016","unstructured":"Hesler RA, Huang JJ, Starr MD, Treboschi VM, Bernanke AG, Nixon AB, et al. TGF-\u03b2-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3. Carcinogenesis. 2016;37:1041\u201351.","journal-title":"Carcinogenesis"},{"key":"3143_CR41","first-page":"110","volume":"8","author":"JR Mackey","year":"2002","unstructured":"Mackey JR, Jennings LL, Clarke ML, Santos CL, Dabbagh L, Vsianska M, et al. Immunohistochemical variation of human equilibrative nucleoside transporter 1 protein in primary breast cancers. Clin Cancer Res. 2002;8:110\u20136.","journal-title":"Clin Cancer Res"},{"key":"3143_CR42","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/2050-6511-14-6","volume":"14","author":"M N\u00fa\u00f1ez","year":"2013","unstructured":"N\u00fa\u00f1ez M, Medina V, Cricco G, Croci M, Cocca C, Rivera E, et al. Glibenclamide inhibits cell growth by inducing G0\/G1 arrest in the human breast cancer cell line MDA-MB-231. BMC Pharmacol Toxicol. 2013;14:6.","journal-title":"BMC Pharmacol Toxicol"},{"key":"3143_CR43","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.canlet.2011.12.021","volume":"332","author":"V Del Gaizo Moore","year":"2013","unstructured":"Del Gaizo Moore V, Letai A. BH3 profiling \u2013 measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions. Cancer Lett. 2013;332:202\u20135.","journal-title":"Cancer Lett"},{"key":"3143_CR44","doi-asserted-by":"publisher","first-page":"7985","DOI":"10.1158\/0008-5472.CAN-08-1418","volume":"68","author":"O Kutuk","year":"2008","unstructured":"Kutuk O, Letai A. Alteration of the mitochondrial apoptotic pathway is key to acquired paclitaxel resistance and can be reversed by ABT-737. Cancer Res. 2008;68:7985\u201394.","journal-title":"Cancer Res"},{"key":"3143_CR45","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1158\/0008-5472.CAN-12-1365","volume":"73","author":"M Rahmani","year":"2013","unstructured":"Rahmani M, Aust MM, Attkisson E, Williams DC, Ferreira-Gonzalez A, Grant S. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism. Cancer Res. 2013;73:1340\u201351.","journal-title":"Cancer Res"},{"key":"3143_CR46","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nprot.2007.30","volume":"2","author":"C-C Liang","year":"2007","unstructured":"Liang C-C, Park AY, Guan J-L. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc. 2007;2:329\u201333.","journal-title":"Nat Protoc"},{"key":"3143_CR47","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/CAD.0000000000000736","volume":"30","author":"E Avsar Abdik","year":"2019","unstructured":"Avsar Abdik E, Kaleagasioglu F, Abdik H, Sahin F, Berger MR. ABT-737 and erufosine combination against castration-resistant prostate cancer: a promising but cell-type specific response associated with the modulation of anti-apoptotic signaling. Anticancer Drugs. 2019;30:383\u201393.","journal-title":"Anticancer Drugs"},{"key":"3143_CR48","doi-asserted-by":"publisher","first-page":"285","DOI":"10.3892\/ijo.2016.3507","volume":"49","author":"Y Yu","year":"2016","unstructured":"Yu Y, Yu X, Ma J, Tong Y, Yao J. Effects of NVP-BEZ235 on the proliferation, migration, apoptosis and autophagy in HT-29 human colorectal adenocarcinoma cells. Int J Oncol. 2016;49:285\u201393.","journal-title":"Int J Oncol"},{"key":"3143_CR49","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1002\/2211-5463.12806","volume":"10","author":"J Cai","year":"2020","unstructured":"Cai J, Xia J, Zou J, Wang Q, Ma Q, Sun R, et al. The PI3K\/mTOR dual inhibitor NVP-BEZ235 stimulates mutant p53 degradation to exert anti-tumor effects on triple-negative breast cancer cells. FEBS Open Bio. 2020;10:535\u201345.","journal-title":"FEBS Open Bio"},{"key":"3143_CR50","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1002\/path.3022","volume":"226","author":"GH Williams","year":"2012","unstructured":"Williams GH, Stoeber K. The cell cycle and cancer. J Pathol. 2012;226:352\u201364.","journal-title":"J Pathol"},{"key":"3143_CR51","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S0037-1963(01)90051-4","volume":"38","author":"Z Darzynkiewicz","year":"2001","unstructured":"Darzynkiewicz Z, Bedner E, Smolewski P. Flow cytometry in analysis of cell cycle and apoptosis. Semin Hematol. 2001;38:179\u201393.","journal-title":"Semin Hematol"},{"key":"3143_CR52","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.3892\/mmr.2017.6182","volume":"15","author":"S Chen","year":"2017","unstructured":"Chen S, Wang Y, Zhang W-L, Dong M-S, Zhang J-H. Sclareolide enhances gemcitabine\u2013induced cell death through mediating the NICD and Gli1 pathways in gemcitabine\u2013resistant human pancreatic cancer. Mol Med Rep. 2017;15:1461\u201370.","journal-title":"Mol Med Rep"},{"key":"3143_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24098136","volume":"24","author":"E-M Packeiser","year":"2023","unstructured":"Packeiser E-M, Engels L, Nolte I, Goericke-Pesch S, Murua Escobar H. MDR1 inhibition reverses doxorubicin-resistance in six doxorubicin-resistant canine prostate and bladder cancer cell lines. Int J Mol Sci. 2023;24:8136.","journal-title":"Int J Mol Sci"},{"key":"3143_CR54","doi-asserted-by":"publisher","first-page":"293","DOI":"10.18632\/genesandcancer.27","volume":"5","author":"KW Kim","year":"2014","unstructured":"Kim KW, Myers CJ, Jung DK, Lu B. NVP-BEZ-235 enhances radiosensitization via blockade of the PI3K\/mTOR pathway in cisplatin-resistant non-small cell lung carcinoma. Genes Cancer. 2014;5:293\u2013302.","journal-title":"Genes Cancer"},{"key":"3143_CR55","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/1756-9966-31-102","volume":"31","author":"J-Y Li","year":"2012","unstructured":"Li J-Y, Li Y-Y, Jin W, Yang Q, Shao Z-M, Tian X-S. ABT-737 reverses the acquired radioresistance of breast cancer cells by targeting Bcl-2 and Bcl-xL. J Exp Clin Cancer Res. 2012;31:102.","journal-title":"J Exp Clin Cancer Res"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03143-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-03143-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03143-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T05:03:06Z","timestamp":1769490186000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-03143-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,20]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["3143"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-03143-z","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,20]]},"assertion":[{"value":"19 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10"}}